Recent Updates
Recently added Catalysts

BON-107

Phase 1

Undisclosed | Small Molecules | Other |BeOne Medicines Ltd.|Trials Updated: Nov 12, 2026

BON-107 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment100

FDA Designations

No designations recorded

BON-107 clinical trials

BON-107 · 1 trial · 1 indication

Phase 1 1
NCT07934069A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of BON-107 in Healthy ParticipantsHealthy Participants
NOT YET_RECRUITING100 Analytics
PHASE1NOT YET_RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of BON-107 in Healthy Participants
Healthy Participants
NCT07934069100
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Adverse Events
From first dose to 30 days after the last dose of study drug; up to approximately 40 days.

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant abnormalities from laboratory tests, vital signs and electrocardiogram results.

Number of Participants with Clinically Significant Change from Baseline in Clinical Laboratory Tests
From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.
Number of Participants with Clinically Significant Change from Baseline in Vital Signs
From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.
Number of Participants with Clinically Significant Change from Baseline in Electrocardiogram Cardiac Conduction Intervals
From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.

Cardiac conduction intervals will be assessed via 12-lead electrocardiogram (ECG).

Secondary Endpoints

Parts A and B: Area Under the Concentration Time Curve (AUC) from Time Zero to Last Quantifiable Time (AUClast) of BON-107
Blood samples will be taken predose and postdose at select time points, up to 7 days after the first or last dose.
Parts A and B: AUC from Time Zero to Infinite Time (AUCinf) of BON-107
Blood samples will be taken predose and postdose at select time points, up to 7 days after the first or last dose.
Parts A and B: AUC from Time Zero to End of Dosing Interval (AUCtau) of BON-107
Blood samples will be taken predose and postdose at select time points, up to 7 days after the first or last dose.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part A: Single Ascending Doses (SAD) of BON-107EXPERIMENTALSequential cohorts of healthy participants will receive a single dose of BON-107 at increasing dose levels.
Part A: PlaceboPLACEBO_COMPARATORSequential cohorts of healthy participants will receive a single dose of matching placebo.
Part B: Multiple Ascending Doses (MAD) of BON-107EXPERIMENTALSequential cohorts of healthy participants will receive multiple doses of BON-107 at increasing dose levels.
Part B: PlaceboPLACEBO_COMPARATORSequential cohorts of healthy participants will receive multiple doses of matching placebo.
Part C: Food Effect of BON-107EXPERIMENTALHealthy participants will take BON-107 in a fed and fasted state, with a washout period between.

Interventions

NameTypeDescription
BON-107DRUGAdministered orally.
PlaceboDRUGAdministered orally.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Healthy participants, defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG, and clinical laboratory tests. * Body Mass Index (BMI) of 18 to 32 kg/m\...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 12, 2026NCT07934069NEW_TRIAL: changed
LOWNov 12, 2026NCT07934069NEW_TRIAL: changed

Explore more on BiopharmaWatch

BeOne Medicines Ltd. (ONC)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with BCompanies A to ZEvery biotech and pharma company we track